Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

SIMPLE SUMMARY: Basal cell carcinoma is the most common skin cancer and new treatments for patients with widespread and numerous tumors are lacking. In a previous study treating patients with multiple myeloma with a peptide vaccine called IO103 against an immune checkpoint molecule called programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Nicolai Grønne, Kaae, Jeanette, Grauslund, Jacob Handlos, Met, Özcan, Nielsen, Signe Ledou, Pedersen, Ayako Wakatsuki, Svane, Inge Marie, Ehrnrooth, Eva, Andersen, Mads Hald, Zachariae, Claus, Skov, Lone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926323/
https://www.ncbi.nlm.nih.gov/pubmed/33671555
http://dx.doi.org/10.3390/cancers13040911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926323/
https://www.ncbi.nlm.nih.gov/pubmed/33671555
http://dx.doi.org/10.3390/cancers13040911

Ejemplares similares